Gavalda Meritxell, Fullana Maria Isabel, Ferre Adrià, Peña Rebecca Rowena, Armendariz Julen, Torrallardona Orla, Magraner Aina, Lorenzo Alejandro, García Carles, Mut Gemma, Planas Lluís, Iglesias Carla, Fraile-Ribot Pablo, Macia Romero Maria Dolores, Riera Melchor, García-Gasalla Mercedes
Internal Medicine Department, Hospital Universitari Son Espases, Illes Balears, Palma, Spain.
Microbiology Department, Hospital Universitari Son Espases, Illes Balears, Palma, Spain.
Can J Infect Dis Med Microbiol. 2024 Mar 19;2024:5948747. doi: 10.1155/2024/5948747. eCollection 2024.
Community-acquired pneumonia is a leading cause of mortality and hospital admissions. The aetiology remains unknown in 30-65% of the cases. Molecular tests are available for multiple pathogen detection and are under research to improve the causal diagnosis.
We carried out a prospective study to describe the clinical characteristics and aetiology of community-acquired pneumonia during the COVID-19 pandemic and to assess the diagnostic effectivity of the microbiological tests, including a molecular test of respiratory pathogens (FilmArray™ bioMérieux).
From the 1st of February 2021 until the 31st of March 2022, 225 patients were included. Failure in microorganism identification occurred in approximately 70% of patients. was the most common isolate. There were 5 cases of viral pneumonia. The tested FilmArray exhibited a low positivity rate of 7% and mainly aided in the diagnosis of viral coinfections.
Despite our extensive diagnostic protocol, there is still a low rate of microorganism identification. We have observed a reduction in and other viral pneumoniae during the COVID-19 pandemic. Having a high NEWS2 score on arrival at the emergency department, an active oncohematological disease or chronic neurological conditions and a positive microbiological test result were related to worse outcomes. Further research is needed to determine the role of molecular tests in the microbiological diagnosis of pneumonia.
社区获得性肺炎是导致死亡和住院的主要原因。30%-65%的病例病因仍不明。分子检测可用于多种病原体检测，目前正在进行相关研究以改善病因诊断。
我们开展了一项前瞻性研究，以描述新冠疫情期间社区获得性肺炎的临床特征和病因，并评估微生物检测的诊断有效性，包括呼吸道病原体的分子检测（FilmArray™ bioMérieux）。
从2021年2月1日至2022年3月31日，共纳入225例患者。约70%的患者微生物鉴定失败。 是最常见的分离株。有5例病毒性肺炎病例。检测的FilmArray阳性率低，为7%，主要有助于诊断病毒合并感染。
尽管我们采用了广泛的诊断方案，但微生物鉴定率仍然较低。我们观察到在新冠疫情期间 和其他病毒性肺炎有所减少。到达急诊科时NEWS2评分高、患有活动性肿瘤血液系统疾病或慢性神经系统疾病以及微生物检测结果呈阳性与较差的预后相关。需要进一步研究以确定分子检测在肺炎微生物诊断中的作用。
